Group 1 - The core point of the article is that Wantai Biological (万泰生物) has seen a significant stock price increase of nearly 5% following the announcement of its nine-valent HPV vaccine receiving approval for market release in China [1][3] - Wantai Biological's subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received the "Biological Product Batch Release Certificate" from the China Food and Drug Administration, marking it as the first domestic company to obtain approval for the nine-valent HPV vaccine after Merck [3] - According to Kaiyuan Securities, the HPV vaccine market in China is expected to expand significantly, potentially reaching a market size of 62.54 billion yuan by 2031, driven by the completion of clinical trials and increased awareness among target populations [3]